Paradigm Biopharmaceuticals (PAR) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Paradigm for Parity® Names Former CEO Sandra Quince as President of Board of DirectorsJanuary 15, 2025 | finance.yahoo.comWhy these small cap ASX shares could deliver very big returns in 2025January 8, 2025 | fool.com.auWhy ANZ, Calix, Paradigm, and Platinum shares are tumbling todayDecember 9, 2024 | msn.comParadigm raises $16m for phase III trial of knee osteoarthritis treatmentDecember 9, 2024 | msn.comPhosCo runs hard on Tunisian phosphateNovember 29, 2024 | msn.comParadigm clear for phase 3 following US FDA reviewNovember 28, 2024 | msn.comWhy did this ASX biotech stock explode 52% higher on Monday?November 25, 2024 | msn.comParadigm Hires Sarah Shulman As VP Corporate CommunicationsNovember 22, 2024 | msn.comParadigm Biopharmaceuticals: Director’s Shareholding UpdateNovember 21, 2024 | markets.businessinsider.comParadigm Biopharmaceuticals Advances with Key ResolutionsNovember 19, 2024 | msn.comParadigm Biopharmaceuticals Targets Growth Amid Market ChallengesNovember 19, 2024 | markets.businessinsider.comParadigm Launches New Division The Sports GroupNovember 15, 2024 | msn.comParadigm Signs NFL’s Aaron Donald, Wife & Business Partner Erica DonaldNovember 12, 2024 | msn.comVincerx Pharma Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | finance.yahoo.comPrilenia Therapeutics B.V.: Prilenia to Present Pridopidine Data at the Huntington Study Group (HSG) 2024 CongressNovember 6, 2024 | finanznachrichten.dePrilenia to Present Pridopidine Data at the Huntington Study Group (HSG) 2024 CongressNovember 6, 2024 | finance.yahoo.comHealth Check: Which biotech boards are at risk of a ‘second strike’?November 4, 2024 | msn.comParadigm Biopharma Advances Phase 3 Trials Amid Financial PrudenceOctober 31, 2024 | markets.businessinsider.comChina’s KKV is now open at JB’s Paradigm Mall — snacks, travel essentials & more from RM2.90October 25, 2024 | sg.style.yahoo.comParadigm Biocapital Advisors LP Acquires Shares in Janux Therapeutics IncOctober 24, 2024 | finance.yahoo.comParadigm Biopharmaceuticals: Director Increases ShareholdingsOctober 23, 2024 | markets.businessinsider.comParadigm Biopharmaceuticals Plans New Securities IssuanceOctober 23, 2024 | markets.businessinsider.comBiotech Alert: Searches spiking for these stocks todayOctober 23, 2024 | markets.businessinsider.comBiocurious: Cracking the code on Paradigm Biopharmaceuticals’ valuation enigmaOctober 22, 2024 | msn.comHealth Check: Just the news we ‘kneed’ as Paradigm aims to kick-start US osteo trialOctober 21, 2024 | msn.comParadigm Biopharmaceuticals Boosts Confidence with Phase 3 PlansOctober 21, 2024 | markets.businessinsider.comParadigm, Episode 8: Hikmat Wehbi, Founder, W StudioOctober 9, 2024 | entrepreneur.comInCarda Therapeutics Announces Results From the RESTORE-1 Phase 3 Trial and Plans for Continued DevelopmentSeptember 30, 2024 | finance.yahoo.comParadigm, Episode 7: Nezha Alaoui, Founder, MayshadSeptember 25, 2024 | entrepreneur.comFDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?September 19, 2024 | msn.comParadigm steps closer to Phase 3 trial for knee arthritis treatment after FDA feedbackSeptember 18, 2024 | msn.comBreak it Down: Paradigm Biopharmaceuticals en route to Phase 3 clinical trial with FDA supportSeptember 18, 2024 | msn.comKorro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic CandidatesSeptember 16, 2024 | markets.businessinsider.comParadigm, Episode 6: Farah Zafar, Co-Founder And CEO, Lyvely And Managing Director, Phoenix GroupSeptember 10, 2024 | entrepreneur.comHow a reunited and rebooted Korn put religious differences aside to make The Paradigm ShiftSeptember 6, 2024 | yahoo.comBioLogic Summit to Demystify the New AI/ML Paradigm in Biologic Drug DevelopmentAugust 20, 2024 | tmcnet.comCantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight RecommendationAugust 17, 2024 | msn.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | msn.comReport: Liv Morgan Signs With Paradigm Talent AgencyAugust 6, 2024 | msn.comWWE Superstar Liv Morgan Signs With Paradigm (EXCLUSIVE)August 6, 2024 | msn.comAvalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of DirectorsAugust 5, 2024 | finance.yahoo.comParadigm Biopharmaceuticals Limited (P86.F)August 5, 2024 | finance.yahoo.comOrna Therapeutics Appoints Nobel Laureate Carolyn Bertozzi, Ph.D., to Scientific Advisory BoardJuly 30, 2024 | finance.yahoo.comNorthStar Medical Radioisotopes Sponsors Study Entitled "Program to Find a Cure for ANCA-associated Vasculitis Through Research"July 30, 2024 | finance.yahoo.comDigital Brand Expressions Announces Launch of A Better ParadigmJuly 29, 2024 | finanznachrichten.deHarbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024July 27, 2024 | msn.comAffyImmune Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AIC100 in Recurrent Anaplastic Thyroid CancerJuly 23, 2024 | finance.yahoo.comEconomic Survey 2024: India’s pharmaceutical sector should start focusing on innovationJuly 22, 2024 | msn.comSherri Saum Signs With ParadigmJuly 20, 2024 | msn.comBigCommerce Scores 24/24 Total Medals in 2024 Paradigm B2B Combine Midmarket and Enterprise Editions for Second Consecutive YearJuly 19, 2024 | tmcnet.com Get Paradigm Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PAR and its competitors with MarketBeat's FREE daily newsletter. Email Address PAR Media Mentions By Week PAR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PAR News Sentiment▼0.000.63▲Average Medical News Sentiment PAR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PAR Articles This Week▼01▲PAR Articles Average Week Get Paradigm Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PAR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Columbia Seligman Premium Technology Growth Fund News Global Payment Technologies News Hauppauge Digital News Invent Ventures News Apple News Arista Networks News Dell Technologies News HP News Hewlett Packard Enterprise News TDK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:PAR) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paradigm Biopharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Paradigm Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
